Scientific Justification and Policy Recommendations to the US Food and Drug Administration for Waiving Comparative Efficacy Studies
This detailed review looks at how the rules for proving biosimilarity are changing, mainly focusing on the requirements for comparative efficacy studies (CESs). As analytical technologies progress, mounting evidence suggests that when we establish robust analytical similarity and pharmacokinetic equ...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/6/779 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849431438285340672 |
|---|---|
| author | Sarfaraz K. Niazi |
| author_facet | Sarfaraz K. Niazi |
| author_sort | Sarfaraz K. Niazi |
| collection | DOAJ |
| description | This detailed review looks at how the rules for proving biosimilarity are changing, mainly focusing on the requirements for comparative efficacy studies (CESs). As analytical technologies progress, mounting evidence suggests that when we establish robust analytical similarity and pharmacokinetic equivalence, CESs become less valuable. This review combines findings from over 600 studies on biosimilars found in PubMed (showing that no biosimilar with proven analytical similarity has ever failed a CES), looks at the differences in global regulations on this topic, and explains how the Food and Drug Administration’s pharmacokinetic testing rules for biosimilars are similar to the bioequivalence testing for generics. Finally, specific changes to the Biologics Price Competition and Innovation Act (BPCIA) are suggested to make US rules match the growing global scientific agreement, which could lower development costs and speed up patient access to biosimilars while still keeping safety and effectiveness intact. |
| format | Article |
| id | doaj-art-9f62a5547db04da5ba12b3cde8cd729c |
| institution | Kabale University |
| issn | 1424-8247 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-9f62a5547db04da5ba12b3cde8cd729c2025-08-20T03:27:39ZengMDPI AGPharmaceuticals1424-82472025-05-0118677910.3390/ph18060779Scientific Justification and Policy Recommendations to the US Food and Drug Administration for Waiving Comparative Efficacy StudiesSarfaraz K. Niazi0College of Pharmacy, University of Illinois, Chicago, IL 60612, USAThis detailed review looks at how the rules for proving biosimilarity are changing, mainly focusing on the requirements for comparative efficacy studies (CESs). As analytical technologies progress, mounting evidence suggests that when we establish robust analytical similarity and pharmacokinetic equivalence, CESs become less valuable. This review combines findings from over 600 studies on biosimilars found in PubMed (showing that no biosimilar with proven analytical similarity has ever failed a CES), looks at the differences in global regulations on this topic, and explains how the Food and Drug Administration’s pharmacokinetic testing rules for biosimilars are similar to the bioequivalence testing for generics. Finally, specific changes to the Biologics Price Competition and Innovation Act (BPCIA) are suggested to make US rules match the growing global scientific agreement, which could lower development costs and speed up patient access to biosimilars while still keeping safety and effectiveness intact.https://www.mdpi.com/1424-8247/18/6/779biosimilarsBPCIAFDAEMAMHRAclinical efficacy study |
| spellingShingle | Sarfaraz K. Niazi Scientific Justification and Policy Recommendations to the US Food and Drug Administration for Waiving Comparative Efficacy Studies Pharmaceuticals biosimilars BPCIA FDA EMA MHRA clinical efficacy study |
| title | Scientific Justification and Policy Recommendations to the US Food and Drug Administration for Waiving Comparative Efficacy Studies |
| title_full | Scientific Justification and Policy Recommendations to the US Food and Drug Administration for Waiving Comparative Efficacy Studies |
| title_fullStr | Scientific Justification and Policy Recommendations to the US Food and Drug Administration for Waiving Comparative Efficacy Studies |
| title_full_unstemmed | Scientific Justification and Policy Recommendations to the US Food and Drug Administration for Waiving Comparative Efficacy Studies |
| title_short | Scientific Justification and Policy Recommendations to the US Food and Drug Administration for Waiving Comparative Efficacy Studies |
| title_sort | scientific justification and policy recommendations to the us food and drug administration for waiving comparative efficacy studies |
| topic | biosimilars BPCIA FDA EMA MHRA clinical efficacy study |
| url | https://www.mdpi.com/1424-8247/18/6/779 |
| work_keys_str_mv | AT sarfarazkniazi scientificjustificationandpolicyrecommendationstotheusfoodanddrugadministrationforwaivingcomparativeefficacystudies |